ICOSLG and melanoma: Interestingly, the same trend has been also observed in B16V murine cells, where usually human oncolytic adenoviruses do not optimally replicate, hence the anti-tumor efficacy of AdV-D24 (42.7%), pembrolizumab (94.7%), and AdV-D24-ICOSL-CD40L (41%) individually or in different combinations on B16V cell line was lower than in human melanoma cells (40.4% and 37.3% for AdV-24 plus anti PD-1 and AdV-D24-ICOSL-CD40L plus anti PD-1, respectively) (Figure S3).